Peer

Integrated mRNA and miRNA profiling in NIH/3T3 cells in response to bovine papillomavirus *E6* gene expression

Feng Pang, Mengmeng Zhang, Guohua Li, Zhenxing Zhang, Haifeng Huang, Baobao Li, Chengqiang Wang, Xiaohong Yang, Yiying Zheng, Qi An, Luyin Zhang, Li Du and Fengyang Wang

College of Animal Science and Technology, Hainan Key Lab of Tropical Animal Reproduction & Breeding and Epidemic Disease Research, Hainan University, Haikou, China

ABSTRACT

Delta bovine papillomaviruses (δ BPVs) mainly infect cattle and cause fibropapillomas. δ BPVs encode three oncogenes, *E5*, *E6* and *E7*. The effect of *E6* on microRNA (miRNA) and mRNA expression profiles is not well characterized. In this study, RNA sequencing and small RNA sequencing were used to explore alterations in mRNAs and miRNAs in E6 over-expressing NIH/3T3 cells (NH-E6) compared with control cells (NH-GFP). We found that 350 genes (181 upregulated and 169 downregulated) and 54 miRNAs (26 upregulated and 28 downregulated) were differentially expressed (DE) following *E6* expression. The top 20 significantly enriched GO terms in "biological process" included inflammatory response, innate immune response, immune response, immune system process, positive regulation of apoptotic process, cell adhesion, and angiogenesis. We constructed a potential miRNA-gene regulatory network from the differentially expressed genes (DEGs) and DE miRNAs. Finally, we selected 19 immune-response related DEGs and 11 DE miRNAs for qPCR validation. Of these, upregulation of 12 genes, Ccl2, Ccl7, Cxcl1, Cxcl5, Tlr2, Nfkbia, Fas, Il1rl1, Ltbp1, Rab32, and Zc3h12a, Dclk1 and downregulation of four genes, Agtr2, Ptx3, Sfrp1, and Thbs1 were confirmed. Ccl2, Ccl7, Cxcl1 and Cxcl5 were upregulated more than ten-fold in NH-E6 compared with NH-GFP. Also, upregulation of three miRNAs, mmu-miR-129-2-3p, mmu-miR-149-5p-R-2 and mmu-miR-222-3p, and downregulation of five miRNAs, mmu-miR-582-3p-R+1, mmu-miR-582-5p, mmu-miR-708-3p, mmu-miR-708-5p and mmu-miR-1197-3p, were confirmed. Our study describes changes in both mRNA and miRNA profiles in response to BPV E6 expression, providing new insights into BPV E6 oncogene functions.

Subjects Bioinformatics, Molecular Biology, Virology

Keywords Bovine papillomavirus, RNA sequencing, miRNA sequencing, E6, Immune response, miRNA-gene network

INTRODUCTION

Papillomaviruses (PVs) are double stranded circular DNA viruses that possess several early open reading frames (ORFs) and two late ORFs (*Bernard et al., 2010; Munday, 2014*). PV genomes are approximately 8000 nucleotides in length (*Bernard et al., 2010*). Bovine papillomaviruses (BPVs) consist of fourteen types that can be classified into four genera:

Submitted 18 April 2019 Accepted 9 July 2019 Published 2 August 2019

Corresponding author Fengyang Wang, fywang68@163.com

Academic editor Yegor Vassetzky

Additional Information and Declarations can be found on page 17

DOI 10.7717/peerj.7442

Copyright 2019 Pang et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

How to cite this article Pang F, Zhang M, Li G, Zhang Z, Huang H, Li B, Wang C, Yang X, Zheng Y, An Q, Zhang L, Du L, Wang F. 2019. Integrated mRNA and miRNA profiling in NIH/3T3 cells in response to bovine papillomavirus *E6* gene expression. *PeerJ* 7:e7442 http://doi.org/10.7717/peerj.7442

Deltapapillomavirus (δ PV), Xipapillomavirus (xPV), Epsilonpapillomavirus (ε PV) and Dyoxipapillomavirus (*Roperto et al., 2016*). Among these, BPV-1, -2, -13 and -14 belong to the δ PV genus and are commonly termed fibropapillomaviruses. They can infect the epithelium and also the underlying derma causing fibropapillomas of the skin and udders, and urinary bladder cancer in cows (*Lubna & Saveria, 2010*; *Shafti-Keramat et al., 2009*). The genome is divided into three regions: the early genes (*E5, E6, E7*) encoding non-structural proteins, the late genes (*L1* and *L2*, encoding viral capsid proteins) and the long control region (LCR) responsible for viral replication and transcription regulation (*Lubna & Saveria, 2010*).

Distinct and typical focus formation could be induced by BPV in two mouse cell lines (NIH/3T3 and C127). Therefore, NIH/3T3 and C127 cells are often used as cell models for cell transformation research in bovine papillomavirus especially in fibropapillomaviruses (*Dvoretzky et al., 1980; OBrien & Campo, 1998; Suprynowicz et al., 2005; Wade, Brimer & Pol, 2008*). In BPV-1, E5 is the major transforming oncoprotein followed by E6, and E7 (*Jackson et al., 1991; Lubna & Saveria, 2010*). The BPV-1 *E6* gene encodes a protein of 137 amino acid residues. BPV E6 can induce cell transformation by binding to the focal adhesion protein, paxillin (*Tong et al., 1997; Tong & Howley, 1997*). E6 can bind to several LD motif (LDXLLXXL) repeats on paxillin and the first LD repeat is the most important for binding E6. The binding between E6 and paxillin can suppress paxillin interacting with multiple cellular proteins, including focal adhesion kinase (FAK) and vinculin (*Tong et al., 1997; Tong & Howley, 1997*).

MicroRNAs (miRNAs) are a large class of endogenous, non-coding, small RNAs of 22–26 nucleotides. miRNAs are found in animals, plants and even in some viruses (*Krol* & *Loedige*, 2010; *Sébastien et al.*, 2004). They participate in multiple biological processes, including cell proliferation, apoptosis and cancer (*Cheng et al.*, 2005; *Murakami et al.*, 2006). Moreover, accumulating evidence indicates that miRNAs play crucial roles in regulating viral replication by targeting the virus genome or cellular proteins (*Chen et al.*, 2017; *Kumar et al.*, 2018; *Tang et al.*, 2016). RNA sequencing is a powerful tool to identify differentially expressed genes in response to viral infection. *Yuan et al.* (2008) performed transcriptional analysis of equine fibroblasts transformed by BPV-1 to identify genes associated with BPV-1 infection. They found that DEGs were significantly enriched in multiple GO terms including "Cell adhesion", "Cell proliferation" and "Inflammation and immunity". However, whether BPV E6, influences host cell miRNA and mRNA expression profiles remains largely unknown.

In the present study, we constructed stable NH-E6 and NH-GFP cells expressing BPV E6 and GFP or GFP alone, respectively. We then performed small RNA sequencing and RNA sequencing to explore alterations in miRNA and gene expression in NH-E6 cells compared with and NH-GFP cells. Our findings provide new insights into the functions of BPV *E6* in the viral life cycle.

MATERIALS AND METHODS

Cell culture

NIH/3T3 and HEK293T cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). They were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS; Grand Island, NY, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Grand Island, NY, USA) at 37 °C in a 5% CO₂ incubator.

E6 codon optimization

To increase the expression level of E6, codon use in the original *E6* gene from BPV (BPV-1, Genbank accession no. X02346; BPV-2, accession no. M20219; BPV-13, accession no. KM258443) was optimized for Mus musculus to avoid rare or low-usage codons (Sangon Biotech, Shanghai, China). The optimized *E6* sequence was synthesized and ligated into pUCK plasmid for Sanger sequencing. Alignment analysis of the original *E6* from BPV-1, -2,-13 (Hainan strain) and the optimized BPV *E6* was presented in Fig. S1.

Lentivirus packaging

The optimized *E6* fragment was cloned into the *Asis* I and *Mlu* I sites of lentiviral plasmid pLent-EF1a-FH-CMV-GFP-P2A-Puro (Vigenebio, Shandong, China). The C-terminus of *E6* was fused with a flag-6 ×his tag (Fig. S2). This recombinant plasmid pLent-EF1a-E6-FH-CMV-GFP-P2A-Puro and the control plasmid were co-transfected with PMD2G and PSPAX2 packaging plasmids into HEK293T cells, respectively. After 72 h, supernatant was collected for purification by ultracentrifugation. Purified recombinant lentivirus and control lentivirus with a high-titer of 1.0×10^8 TU/ml (transducing units/ milliliter) were collected and stored at -70 °C.

Generation of NH-E6 and NH-GFP stable cell lines

When NIH/3T3 cells seeded in a 24-well plate reached approximately 50% confluency, they were infected with recombinant lentivirus or negative control lentivirus at a multiplicity of infection (MOI) of 50. After three days, cells were subcultured and selected for puromycin resistance (Solarbio, Beijing, China) at 1 µg/mL. One week later, we acquired a polyclonal NH-GFP stable cell line and a polyclonal NH-E6 stable cell line. An IX71 fluorescence microscope (Olympus, Tokyo, Japan) was used to observe the number of cells stably expressing GFP in NH-GFP and NH-E6 stable cells. Total RNA was extracted from a dish of NIH/3T3, NH-GFP and NH-E6 cells, respectively using an Animal Tissue RNA Purification Kit (Product #TRK-1002; LC Sciences, Hangzhou, China). Then RT-PCR was performed using a HiScript II One Step RT-PCR Kit (Vazyme, Nanjing, China) with optimized E6 primers (5'-3'):E6-F:ATGGACCTTCAGTCCTTCAGC; E6-R:TCACGGATACTTAGACCTTGAGCC and GAPDH primers (Table 1) following the manufacturer's procedures. Approximately 60 µg cellular protein from NH-GFP and NH-E6 cells were used for western blot (WB) analysis. A mouse monoclonal anti-FLAG M2 primary antibody 1:2000 (Sigma-Aldrich, Shanghai, China) and a goat anti-mouse IgG-HRP secondary antibody 1:5000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used to detect E6-flag. A goat polyclonal Glyceraldehyde-3-phosphate dehydrogenase

CallF:CAGCallR:GTCCallF:CCAR:ACAR:ACACxdlF:ACTCxdlF:GCACxdlF:GCACxdlF:GCACxdlF:GCACxdlF:GCACxdp1F:ACTCxdp1F:TGGCxdp1F:TGGCxdp1F:CTTCxdp1F:CTTCxdp1F:CTTCxdp1F:CTTCxdp1F:CTTCxdp1F:CTTCxdp1F:CGACxdp1F:GCACxdp	er sequence(5'-3')
Cal7 F: CA Cxcl1 F: ACI Cxcl5 F: GCA Cxcl7 F: GCA Cxcl8 F: GCA Cxcl8 F: GCA Cxcl7 F: GCA Cxcl7 F: GCA Cxcl8 F: GCT Cxcl7 F: GCA	GTCCCTGTCATGCTTCT
R:ACACxcl1F: ACIR:TGGCxcl5F:GCAR:CGTIllr11F:AAAR:ATGCtbp1F:TGGR:AAAChp1F:TGGR:CAAScl10F:CTFR:GCAVjkbiaF:CGAR:GCAVjkbiaF:GGAR:GTCCablaR:GTCCablaF:GGCCablaF:GGCCablaF:GGCCablaF:GGCCablaF:GGCCablaF:GGTCabla </td <td>GGGGCGTTAACTGCATCT</td>	GGGGCGTTAACTGCATCT
R:ACACxcl1F: ACIR:TGGCxcl5F:GCAR:CGTIllr11F:AAAR:ATGCtbp1F:TGGR:AAAChp1F:TGGR:CAAScl10F:CTFR:GCAVjkbiaF:CGAR:GCAVjkbiaF:GGAR:GTCCablaR:GTCCablaF:GGCCablaF:GGCCablaF:GGCCablaF:GGCCablaF:GGCCablaF:GGTCabla </td <td>ACATGCTGCTATGTCAAGA</td>	ACATGCTGCTATGTCAAGA
RTGG Cxcl5 F:GCA R:CGT R:CGT Illrl1 F:AAA Ctbp1 F:TGG Ctbp1 F:TGG R:CTA R:AAA Clr2 F:TCT Bd10 F:CTT Sd10 F:CTT Sd10 F:CTT Sd20 R:GCA Vfkbia F:CGA R:GCA R:GCA Sd10 F:CTT Sd10 F:CTT Sd2 R:GCA Vfkbia F:CGA R:ACT R:GCA Sd10 F:GCT Rab32 F:CGT R:AGC R:AGC Ptx3 F:CGT Chbs1 F:CAA Sfip1 F:GCT R:Ab10 F:GGC R:GTO R:GCC Sfip1 F:GCT R:Ab10 F:GCT	ACCGACTACTGGTGATCCT
Cxcl5 F.GCA R:CGT R:CGT Illrl1 F.AAA Ctbp1 F.TGG Ctbp1 F.TGG R:AAA R:AAA Clr2 F.TCT Bcl10 F.CTT Sc110 F.CTT Sc110 F.CTT Sc20 R:GCA Vfkbia F.CGT Cabba R:GTC Fas F.TGCC Dclk1 F.GTCT Rab32 F.CGT Rab32 F.CGT Crm35 F.AAC Rict3 F.GGT Crm35 F.AAC Rict3 F.CGT Rict4 R:CGT Rict3 F.CGT Rict4 R:CGT Rict5 F.CAA Rict6 R:CGT Rict6 R:CGT Rict6 R:GGT Rict6 R:GGT Rict6 R:GGT Rict6 R:GGT Rict6 R:GGT Rict6 R:GGT Ri	TGCACCCAAACCGAAGTC
R:GT IIIrli F:AAA R:ATG R:AAA FI'2 R:CTA Ballo F:CT R:GCA Scillo F:CT Scillo F:CT Scillo F:CT R:GCA R:GCA R:GCA R:GCA R:AGCA R:AGCA <	GGGACACCTTTTAGCATCT
IIIrli F:AAA R:ATG R:ATG Ctbp1 F:TGG R:AAA R:AAA Flr2 F:TCT Bd10 F:CTT Bd10 F:CGA R:GCA R:GCA Nfkbia F:CGA R:GTC R:GTC Fas F:TGC Dclk1 F:GTC R:Ab32 F:CGT R:ab32 F:CGT Crim35 F:AAC R:AAG R:AGC Ptx3 F:CGT Cfbs1 F:CGT R:Ab30 F:CGT R:AAG R:AGC Ptx3 F:CGT R:Ab10 F:GCT R:Ab10 F:GCT	ACTCGCAGTGGAAAGAAC
R:ATG Ltbp1 F:TGG R:AAA R:AAA Flr2 F:TCT Bcl10 F:CTT Scl10 F:CGT R:ACD F:GTC Scl11 F:GTC R:ACD F:GTC Scl11 F:GTC R:ACD F:GTC Scl11 F:GTC R:ACD F:GTC R:ACD F:GTC R:ACD R:GTC R:ACD R:G	IGGGTGGAGAGAATCAGC
Ltbp1 F:TGG R:AAA R:AAA Flr2 F:TCT Bd10 F:CTT Bd10 F:CTT Sd10 F:CGA Nfkbia F:CGA R:GTC R:GTC Fas F:TGC Dclk1 F:GTC Rab32 F:CGT Frim35 F:AAC Ptx3 F:CGT Chbs1 F:CGT Sfrp1 F:CAA Rab10 F:GGC	ATTCTATGATGGGCGGGT
R:AAA Flr2 F:TCT Bcl10 F:CTA Scl10 F:CTA Nfkbia F:CGA R:GTC R:ACD Call F:GTC Scl11 F:GTC Call F:GTC Rab32 F:CGT R:AGC F:CGT R:AGC P:CGT R:AGC P:CGT R:AGC P:CGT R:AGC P:CGT P:tx3 F:CGT Chbs1 F:CGT R:TAG R:CGC S/frp1 F:GCT R:ab10 F:GGC R:GTC R:GTC R:GTC R:GTC R:GTC R:GCC S/frp1 F:GCC R:B10 F:GCC R:GTC R:GTC R:GTC R	GGTGTGTTCACTAGGCGG
FIr2 F:TCT. Bcl10 F:CTA Scl10 F:CTA Nfkbia F:CGA Nfkbia F:CGA R:GTC F:TGC Fas F:TGC Dclk1 F:GTC Rab32 F:CGT R:A32 F:CGT Rigtr2 F:TGC Ptx3 F:CGT R:TAG R:TAGC Sfrp1 F:GCT R:Ab10 F:GGC R:GTC R:TAGC Sclipp1 F:GGC R:B10 F:GGC	GACGACCCCTAGCAATGA
RicTA RicTA RicTA RicTA RicTA RigCA Vfkbia FiCGA RigTC Fas FiTGC RicTA RigTC Pas Rib32 FiCGT RicTT Frim35 FiAAC RicTT Frim35 FiAAC RicTT Frim35 FiAAC RicTT RicTT Frim35 FiAAC RicTT RicTT FiAAC RicTT RicTT FiAAC RicTT RicTT FiAAC RicTT RicTT FiAAC RicTT RicTT FiAAC RicTT R	AGGCCCCTCAAGGAAGTG
Ball0 F:CTT R:GCA R:GCA Vfkbia F:CGA Fas F:TGC Colk1 F:GTC Dclk1 F:GTC Rab32 F:CGT Rab10 F:GGC R:GT0 F:GGC R:GT0 F:GGC R:GT1 F:GGC Rab10 F:GGC	CAAAGTCGATCCGCGACAT
R:GCA Nfkbia F:CGA R:GTC R:GTC Fas F:TGC Colk1 F:GTC Dclk1 F:GTC Rab32 F:CGT R:m35 F:AAC Rigtr2 F:TGC Ptx3 F:CGT R:TAG R:CGC Sfrp1 F:GCT R:Ab10 F:GGC	ACGGGCAGTGGTGAAAACT
Njfkbia F:CGA Fas F:TGC Fas F:TGC Colk1 F:GTC Dolk1 F:GTC Rab32 F:CGT Rab32 F:CGT Trim35 F:AAC Agtr2 F:TGC Ptx3 F:CGT Fibbs1 F:CAA S/frp1 F:GCT Rab10 F:GGC	CAAGTAGAAAACGGGCTG
Right Right Fas FiTGC Fas FiTGC Dclk1 FiGTC Rab32 FiCGT Rab32 FiCGT Rab35 FiAAC Rab37 FiAAC Rab32 FiCGT Rimma5 FiAAC Rimma5 FiAAC Agtr2 FiTGC Ptx3 FiCGT Fibs1 FiCAA RicCCG Sfrp1 Rab10 FiGGC Right0 FiGGC	ACCTAGAGAGGTTGTTGGT
Fas F:TGC Ras F:TGC Dclk1 F:GTC Rab32 F:CGT Rab32 F:CGT Trim35 F:AAC Agtr2 F:TGC Ptx3 F:CGT Chbs1 F:CAA Sfrp1 F:GCT Rab10 F:GGC	AGACTTTCGAGGAAATACC
R: ACT Podk1 F:GTC R:ATG R:ATG R:ATG R:ATG R:GTT F:CGT R:AAG Agtr2 F:TGC Ptx3 F:CGT R:AAG Ptx3 F:CGT R:TAG F:CGT R:TAG F:CAA R:CCG F:CGT R:TAG R:CCG F:CGT R:TAG R:CCG F:CGT R:TAG R:CCG F:CGT R:TAG R:CCG F:CGT R:CCG	CTGCGTCAAGACTGCTACA
Ddk1 F:GTC Rab32 F:CGT Rab32 F:CGT Rrim35 F:AAC Agtr2 F:TGC Ptx3 F:CGT Chbs1 F:CAA Sfrp1 F:GCT Rab10 F:GGC	CTGGCTCACAGTTAAGAGT
Rab32 F:CGT Rab32 F:CGT Irim35 F:AAC Raftr2 F:TGC Ptx3 F:CGT Chbs1 F:CAA Sfrp1 F:GCT Rab10 F:GGC	TCCTTCCCTTCTGTGCAT
Rab32 F:CGT R:GTT R:GTT Frim35 F:AAC R:AAG R:AAG Agtr2 F:TGC Ptx3 F:CGT R:TAG R:TAG Fibs1 F:CAA Sfrp1 F:GCT Rab10 F:GGC	CAAGACCACCTCAGCCTC
R:GTT Frim35 F:AAC R:AAG Agtr2 F:TGC Ptx3 F:CGT R:TAG Fibs1 F:CAA R:CCG Sfrp1 F:GCT R:TAC Rab10 F:GGC	GATGGTGACCAGCTTGGG
Frim35 F:AAC R:AAG R:AAG Agtr2 F:TGC R:AGC R:AGC Ptx3 F:CGT R:TAG R:TAG Fhbs1 F:CAA Sfrp1 F:GCT Rab10 F:GGC R:GTG R:GTG	GGGTAAGACGAGCATCA
R:AAG Agtr2 F:TGC R:AAG Ptx3 F:CGT R:TAG Ptbs1 F:CAA R:CCG Sfrp1 F:GCT R:TAG R:AGC R:AGC R:TAG R:CCG Sfrp1 F:GGC R:TAC R:AGC R:TAG R:CCG R:F0 F:GGC R:GTG	IGCCAAACCGTTCCTGTC
Agtr2 F:TGC R:AGC R:AGC Ptx3 F:CGT R:TAG R:TAG Fhbs1 F:CAA R:CCG R:CCG Sfrp1 F:GCT Rab10 F:GGC R:GTG R:GTG	CACAAGAGCCGAAAACGC
R:AGC Ptx3 F:CGT R:TAG R:TAG Fhbs1 F:CAA R:CCG F:CGC Sfrp1 F:GCT R:TAC R:TAC Rab10 F:GGC R:GTG R:GTG	GCTGAAGGGCACAGACTC
Ptx3 F:CGT R:TAG R:TAG Fbbs1 F:CAA R:CCG R:CCG Sfrp1 F:GCT R:TAG R:TAG Rab10 F:GGC R:GTG R:GTG	CTCTGACCTGGATGGGTA
R:TAG Fhbs1 F:CAA R:CCG Sfrp1 F:GCT R:TAC Rab10 F:GGC R:GTG	CTGTTGGTGAATCCCAGG
Fhbs1 F:CAA R:CCG R:CCG Sfrp1 F:GCT R:TAC R:TAC Rab10 F:GGC R:GTG R:GTG	IGCATCCTGTGAGACCAA
R:CCG Frp1 F:GCT R:TAC Rab10 F:GGC R:GTG	GGGGTTCCACTTTGTGCC
Sfrp1 F:GCT R:TAC Rab10 F:GGC R:GTG	ATTTTCAGGGGGGTGCTGC
R:TAC Rab10 F:GGC R:GTC	GTTCACCACGTTGTTGTC
Rab10 F:GGC R:GTC	IGCTCAACAAGAACTGCC
R:GTC	CCTTGGGGGCTTAGAGGCT
	CAAGACCTGCGTCCTTTT
Zc3h12a F:ACG	GATGGTGTGAAATCGCTCC
	GAAGCCTGTCCAAGAATCC
	TAGGGGCCTCTTTAGCCAC
1	TGTCCGTCGTGGATCTGA TGCTTCACCACCTTCTTGA

(GAPDH) primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:2000, and a HRP-conjugated rabbit anti-goat IgG (Boster Biotechnology company, Wuhan, China) 1:5000 were used to detect the internal control GAPDH.

RNA isolation and **RNA**-seq

Three total RNA isolations from a polyclonal NH-GFP /NH-E6 stable cell line were prepared respectively using an Animal Tissue RNA Purification Kit (Product #TRK-1002; LC Sciences, Hangzhou, China).

Poly (A) RNA is purified from total RNA (2 µg) using poly-T oligo-attached magnetic beads. Following purification, the mRNA is fragmented into small pieces. Then the cleaved RNA fragments were reverse-transcribed to create the cDNA library using the mRNASeq sample preparation kit (Illumina, San Diego, USA), the average insert size for the paired-end libraries was 300 bp (\pm 50 bp). Then we performed the paired-end sequencing on an Illumina Hiseq4000 platform (LC Sciences, Hangzhou, China). The raw reads with low quality were removed to acquire the valid reads, which were aligned to UCSC (http://genome.ucsc.edu/) Mus musculus reference genome (Accession ID: GCA_000001305.2) using HISAT package. The mapped reads of each sample were assembled using StringTie. StringTie and edgeR was used to estimate the expression levels of all transcripts. StringTie was used to evaluate expression level for mRNAs by calculating FPKM (fragments per kilobase of exon per million reads mapped). Differentially expressed mRNAs and genes were selected with fold change ≥ 2 or fold change ≤ 0.5 and with statistical significance ($p \leq 0.05$) by R package. The raw and processed data have been deposited into the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE129593.

miRNA sequencing

In parallel, the same total RNA was used for small RNA sequencing using an Illumina HiSeq 2500 platform from LC Sciences (Hangzhou, China). Raw reads were subjected to an in-house program, ACGT101-miR (LC Sciences, Houston, TX, USA) to remove adapter dimers, junk, low complexity, common RNA families (rRNA, tRNA, snRNA, snoRNA) and repeats. Subsequently, unique sequences with length in 18 ~ 26 nucleotide were mapped to Mus musclus precursors in miRBase 22.0 by BLAST search to identify known miRNAs and novel -3p and -5p derived miRNAs. Read counts to tags per million counts (TPM) was used to normalize the expression levels of miRNAs. Differentially expressed miRNAs were identified by fold change \geq 1.4 or fold change \leq 0.71, and $p \leq$ 0.05. The raw and processed data have been deposited into the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE129592.

GO enrichment analysis of DEGs

The Gene Ontology resource (GO; http://geneontology.org) is the most comprehensive and widely used knowledge-base concerning the functions of genes. GO has three ontologies including biological process, molecular function and cellular component. The basic unit of GO is GO-term. GO enrichment analysis provides the GO terms significantly enriched of

DEGs compared with the genome background calculated by hypergeometric test (*Ashburner et al., 2000; Gene Ontology Consortium, 2018*).

$$\mathbf{P} = 1 - \sum_{i=0}^{m-1} \frac{\binom{M}{i} \binom{N-M}{m-i}}{\binom{N}{n}}$$

N: The number of all genes with GO annotation; n: The number of DEGs in N; M: The number of all genes annotated to certain GO terms; m: The number of DEGs in M. GO terms with $p \le 0.05$ are defined as significantly enriched GO terms in DEGs.

KEGG enrichment analysis of DEGs

The Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.kegg.jp/) is an encyclopedia of genes and genomes, which is the major public pathway-related database. Pathway enrichment analysis identifies significantly enriched pathways in DEGs relative to the whole genome background by hypergeometric test (*Kanehisa et al., 2017; Kanehisa et al., 2011*). The formula is the same as that used in GO analysis. N, The number of all genes with KEGG annotation; n, The number of DEGs in N; M, The number of all genes annotated to specific pathways; m, The number of DEGs in M. Pathways with $p \le 0.05$ are defined as significantly enriched KEGG pathways in DEGs.

Integrated analysis of differentially expressed miRNAs and genes

TargetScan 7.0 and Miranda software (2010 release) were used to predict the target genes of DE miRNAs. TargetScan score percentiles \geq 50 and Miranda max free energy values \leq -10 were the cutoff points for targets prediction. The inversely correlated DE miRNAs and DEGs from RNA-seq were used to construct miRNA-mRNA networks using Cytoscape 3.6.0 software as described previously (*Pang et al., 2019*).

qRT-PCR validation of differentially expressed genes and miRNAs

To assess the reliability of the RNA-seq and small RNA sequencing, we conducted qRT-PCR validation as previously described. Briefly, total RNA of each sample was reverse transcribed to cDNA using an M-MLV GIII First-Strand Synthesis Kit (with DNase I) (Yugong Biolabs). Then, qPCR was performed using ChamQ Universal SYBR qPCR Master Mix (Vazyme, Nanjing, China) on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The specific primers of 19 immune-associated DEGs were listed on Table 1. For miRNA validation, specific stem-loop primers were used to reverse transcribe miRNAs according to the miRNA 1st Strand cDNA Synthesis kit (Vazyme, Nanjing, China). Then, qPCR were performed using miRNA Universal SYBR qPCR Master Mix (Vazyme, Nanjing, China) with specific forward primers (F) and the universal reverse primer within the kit following the manufacturer's protocols. The specific stem-loop primers and forward primers of the DE miRNAs were listed on Table 2. All experiments were conducted independently three times.

Statistical analysis

Student's *t*-test was used to assess statistical significance. $p \le 0.05$ indicated significant difference between two groups.

Table 2 Sp	ecific stem-loop	primers and for	ward primers for D	E miRNAs validation.
------------	------------------	-----------------	--------------------	----------------------

Primers	Primer sequence(5'-3')
mmu-miR-582-5p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGTAACT
mmu-miR-582-5p-F	GCGCGATACAGTTGTTCAACC
mmu-miR-708-3p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTAGAA
mmu-miR-708-3p-F	CGCGCAACTAGACTGTGAGC
mmu-miR-1197-3p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGAAGT
mmu-miR-1197-3p-F	GCGCGTAGGACACATGGTCT
mmu-miR-708-5p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCCAGC
mmu-miR-708-5p-F	GCGCGAAGGAGCTTACAATCTA
mmu-miR-582-3p-R+1-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGGTTCA
mmu-miR-582-3p-R+1-F	GCGCGTAACCTGTTGAACAAC
mmu-miR-224-5p_R+1-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAACGG
mmu-miR-224-5p_R+1-F	CGCGCGTAAGTCACTAGTGGTT
mmu-miR-222-3p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGACCC
mmu-miR-222-3p-F	CGCGAGCTACATCTGGCTACT
mmu-miR-29b-3p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAACACT
mmu-miR-29b-3p-F	CGCGTAGCACCATTTGAAATC
mmu-miR-129-2-3p-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACATGCTT
mmu-miR-129-2-3p-F	CGAAGCCCTTACCCCAAA
mmu-miR-93-3p_R+1-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCGGGA
mmu-miR-93-3p_R+1-F	GCGACTGCTGAGCTAGCACT
mmu-miR-149-5p_R-2-loop	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGAGTGA
mmu-miR-149-5p_R-2-F	GCGTCTGGCTCCGTGTCT
Universal Reverse Primer	AGTGCAGGGTCCGAGGTATT
U6-F	CGCTTCGGCAGCACATATACTA
U6-R	CGCTTCACGAATTTGCGTGTCA

RESULTS

Generation of NH-E6 and NH-GFP stable cell lines

Sanger sequencing showed that the optimized *E6* gene had 100% amino acid identity with the wild-type gene. We observed more than 90% cells from both NH-GFP and NH-E6 group expressing bright green fluorescence. The fluorescence intensity from NH-GFP cells was a little stronger than that from NH-E6 cells (Figs. 1A, 1B). RT-PCR results indicated that the optimized *E6* gene (414 bp) could only be amplified from NH-E6 stable cells and the PUCK-E6 positive plasmid but not from NH-GFP stable cells or NIH/3T3 cells (Fig. 1C). The internal control GAPDH (110 bp) could be amplified from NIH/3T3 cells and NH-GFP and NH-E6 stable cells (Fig. 1D). The WB results indicated that a 16 kDa E6-flag protein could be detected in NH-E6 cells but not in NH-GFP cells (Fig. 1E, Fig. S3). GAPDH, a protein loading control, was detected at 37 kDa in both NH-GFP and NH-E6 samples (Fig. 1F, Fig. S3).



Figure 1 Generation of NH-E6 and NH-GFP stable cell lines. (A), (B) Images of NH-E6 and NH-GFP stable cell lines. (C), (D) BPV E6 mRNA detection by RT-PCR. The optimized E6 gene (414 bp) could only be amplified from NH-E6 stable cells and the PUCK-E6 positive plasmid but not from NH-GFP stable cells or NIH/3T3 (NH) cells. The internal control GAPDH (110 bp) could be amplified from NH sample and NH-GFP and NH-E6 stable cells. NH sample was a blank control, while PUCK-E6 plasmid was a positive control. (E), (F) BPV-13 E6 protein detection by western blot. The E6-flag fusion protein could be detected in approximately 16 kDa in NH-E6 samples while not in NH-GFP samples. The mouse GAPDH (37 kDa) was an internal control.

Full-size 🖾 DOI: 10.7717/peerj.7442/fig-1

Comparison of differentially expressed genes and miRNAs between NH-E6 and NH-GFP cells

According to the filter criteria, fold change ≥ 2 or fold change ≤ 0.5 and $p \leq 0.05$ between NH-E6 and NH-GFP samples, 350 DEGs were identified. Among these, 181 were upregulated while the other 169 were downregulated (Figs. 2A, 2B). The clustered heatmap revealed a high degree of similarity among samples within the same group and showed that the BPV-13 *E6* gene significantly altered the gene expression profile of NIH/3T3 cells.

Through small RNA sequencing, we identified 26 upregulated and 28 downregulated genes according to the cutoff, fold change ≥ 1.4 or fold change ≤ 0.71 and $p \leq 0.05$. The upregulated and downregulated miRNAs with mean TPM ≥ 50 in NH-GFP and NH-E6 groups are presented in Tables 3 and 4. The heatmap is shown in Fig. 2C.



Figure 2 Analysis of differentially expressed genes (DEGs) and miRNAs in NH-E6 cells compared with NH-GFP cells. (A) Heatmap of the upregulated and downregulated genes. (B) Volcano plot of DEGs. Vertical lines correspond to 2-fold changes in upregulation and downregulation. Horizontal line represents p 0.05. The red and blue dots represent upregulated and downregulated genes, respectively, while the gray dots represent genes with no significant difference. (C) Heatmap of differentially expressed miRNAs (fold change \geq 1.4 or fold change \leq 0.71 and $p \leq$ 0.05 and mean TPM \geq 50). Full-size \square DOI: 10.7717/peerj.7442/fig-2

GO analysis of DEGs between NH-E6 and NH-GFP samples

Next, we conducted GO analysis of the DEGs from NH-E6 vs NH-GFP samples to gain further insight into the biological processes that are potentially regulated by these genes. There were hundreds of enriched GO terms ($P \le 0.05$). The top 20 significantly enriched biological processes included cell adhesion, cell cycle arrest, positive regulation of cell proliferation and apoptotic process, angiogenesis, inflammatory response, innate immune response, immune response, and immune system process (Fig. 3A). Furthermore, several

miR_name	fold_change	p	
mmu-miR-877-3p_L-2R+2	1.523507	1.45E-05	
mmu-miR-344b-3p	1.776455	4.68E-05	
mmu-miR-222-3p	1.439084	0.00019	
mmu-miR-149-5p_R-2	1.92352	0.000887	
mmu-miR-140-3p_L-1R+2	1.465576	0.001236	
mmu-miR-222-5p	1.408298	0.004782	
mmu-miR-129-5p	1.652894	0.004923	
mmu-miR-342-3p_R+1	1.53254	0.004923	
mmu-miR-3068-5p_R-1	1.547281	0.005926	
mmu-miR-29b-3p	1.465812	0.006142	
mmu-miR-129-2-3p	2.1222	0.006466	
mmu-miR-181c-5p	1.515633	0.007845	
mmu-miR-126a-3p_R-1	1.572056	0.00846	
mmu-miR-218-5p_R+1	1.825007	0.010685	
mmu-miR-93-3p_R+1	1.476632	0.016594	
mmu-miR-145a-5p	1.451619	0.019651	
mmu-miR-10b-5p_R-1	1.416059	0.02047	
mmu-miR-140-5p	1.530396	0.028355	
mmu-miR-126a-5p	1.448833	0.034403	
mmu-miR-19b-3p	1.531771	0.041923	
mmu-miR-6690-5p	1.423879	0.047297	
mmu-miR-669f-3p	1.491341	0.012996	
mmu-miR-877-5p_R+4	1.568047	0.001093	

Table 3 Upregulated miRNAs in NH-E6 samples compared with NH-GFP samples (mean TPM ≥ 50).

significantly enriched GO terms were associated with the immune response, including inflammatory response, innate immune response, immune response, toll-like receptor signaling pathway, response to virus, chemokine-mediated signaling pathway, NF-kappaB signaling, antigen processing and presentation, as shown in Table 5.

KEGG analysis of DEGs between NH-E6 and NH-GFP samples

Thirty-six KEGG pathways were significantly enriched ($P \le 0.05$). The top 20 pathways included the IL17 signaling pathway, the TNF signaling pathway, the influenza A, NF-kappa B signaling pathway, the B cell receptor signaling pathway, the cytosolic DNA-sensing pathway, and the Toll-like receptor signaling pathway (Fig. 3B). Details of several significantly enriched pathways related to the immune response are shown in Table 6.

Construction of a miRNA-gene network

To increase stringency, only DEGs with FPKM \geq 5 and DE miRNAs with mean TPM \geq 50 in at least one group (NH-GFP or NH-E6) were used to build a network to identify crucial miRNAs and genes in the regulatory network (Fig. 4). Thus, a total of 160 DEGs (94 upregulated, 56 downregulated) and 38 DE miRNAs (23 upregulated, 13 downregulated) were selected. We found that some miRNAs could bind several targets. For example, *mmu-miR-582-5p* potentially regulated nine targets: *Rcan2*, *Tlr2*, *Snn*, *Cxcl5*, *Alg10b*,

miR_name	fold_change	Þ
mmu-miR-582-5p	0.490304	0.000208
mmu-miR-146b-5p_R+2	0.609482	0.000557
mmu-miR-224-5p_R+1	0.284312	0.001878
mmu-miR-33-5p_R-1	0.576622	0.002356
mmu-miR-582-3p_R+1	0.628812	0.002577
mmu-miR-155-5p	0.619107	0.004662
mmu-miR-1197-3p	0.649636	0.006704
mmu-miR-125b-2-3p	0.61189	0.009256
mmu-miR-708-3p	0.618296	0.019788
mmu-miR-708-5p	0.702115	0.027376
mmu-miR-1193-5p_L+1	0.703607	0.02951
mmu-miR-296-3p	0.586906	0.049283
bta-miR-378_R+1_1ss22CA	0.614734	0.028937
mmu-miR-203-3p_L-1R+1	0.367714	0.021549
mmu-miR-547-3p_R+1	0.501073	0.011543

Table 4Downregulated miRNAs in NH-E6 samples compared with NH-GFP samples (meanTPM \geq 50).

Msantd4, *Rhoq*, *Ltbp1*, and *Hspa13*. Also, some miRNAs shared common targets. For instance, *Hspa13* was regulated by *mmu-miR-582-5p*, *mmu-miR-547-3p-R+1* and *mmu-miR-125b-2-3p*. These results indicate that a potential miRNA-gene regulatory network exists in BPV *E6* over-expressing NIH/3T3 cells.

qPCR validation of DEGs and DE miRNAs

Based on GO and KEGG analyses, we selected 19 immune response-related DEGs (FPKM \geq 5 in NH-GFP or NH-E6 groups) for qPCR validation, including 13 upregulated genes, chemokine (C-C motif) ligand 2 (Ccl2), chemokine (C-C motif) ligand 7 (Ccl7), chemokine (C-X-C motif) ligand 1 (Cxcl1), chemokine (C-X-C motif) ligand 5 (Cxcl5), toll-like receptor 2 (Tlr2), interleukin 1 receptor-like 1 (Il1rl1), nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha (Nfkbia), B cell leukemia/lymphoma 10 (Bcl10), latent transforming growth factor beta binding protein 1 (Ltbp1), TNF receptor superfamily member 6 (Fas), doublecortin-like kinase 1 (Dclk1), RAB32, member RAS oncogene family (Rab32) and zinc finger CCCH type containing 12A (Zc3h12a) and six downregulated genes, angiotensin II receptor, type 2 (Agtr2), RAB10, member RAS oncogene family (Rab10), tripartite motif-containing 35 (Trim35), pentraxin related gene (Ptx3), secreted frizzled-related protein 1 (Sfrp1) and thrombospondin 1 (Thbs1). The qPCR results were consistent with the RNA-seq results for all genes except for Bcl10, Trim35 and Rab10 (Fig. 5A). Among the DE miRNAs in both NH-GFP and NH-E6 groups whose mean TPM >50, we randomly selected five upregulated miRNAs: mmu-miR-29b-3p, mmu-miR-93-3p-R+1, mmu-miR-129-2-3p, mmu-miR-149-5p-R-2, and mmu-miR-222-3p and six downregulated miRNAs: mmu-miR-224-5p-R+1, mmu-miR-582-3p-R+1, mmumiR-582-5p, mmu-miR-708-3p, mmu-miR-708-5p and mmu-miR-1197-3p for qPCR validation. The qPCR results were consistent with the small RNA sequencing results for all



Figure 3 GO and **KEGG** analyses of differentially expressed genes in NH-E6 samples compared with NH-GFP samples. (A) GO enrichment analysis of DEGs. Top 20 GO terms ($p \le 0.05$) in biological processes, cellular components and molecular functions are presented. Left *Y*-axis represents the absolute gene counts enriched in the term; right *Y*-axis represents % of the genes enriched in the GO term compared to the total number of genes enriched in top 20 GO terms in three ontologies. (B) KEGG pathway enrichment analysis of DEGs. Top 20 KEGG pathways ($p \le 0.05$) are presented. *Y*-axis represents pathways; *X*-axis represents rich factor; (rich factor equals the ratio between the DEGs and all annotated genes enriched in the pathway); The color and size of each bubble represent enrichment significance and the number of DEGs enriched in a pathway, respectively.

Full-size DOI: 10.7717/peerj.7442/fig-3

GO_ID	GO_Term	Genes	Þ
GO:0006954	inflammatory response	Agtr2;Aim2;C3;C4b;Ccl2;Ccl7;Cxcl10;Cxcl1;Cxcl5;Cyp26b1; Fas;Nfkbiz;Relb;Sema7a;Thbs1;Tlr2;Tlr4;Tnfaip3;Zc3h12a	0.00
GO:0050729	positive regulation of inflammatory response	Il1rl1;Il33;Nfkbia;Ptger4;Tlr2;Tlr4	0.00
GO:0045087	innate immune response	Aim2;Bcl10;C3;C4b;Ighm;Oas3;Ptx3;Relb;Syk;Tgtp1; Gm12185;Tlr2;Tlr4;Trem2;Trim35	0.00
GO:0006955	immune response	Ccl2;Ccl7;Cxcl10;Cxcl1;Cxcl5;Fas;Oas3;Ptger4; Tgtp1;Gm12185;Thbs1	0.00
GO:0070098	chemokine-mediated signaling pathway	Ccl2;Ccl7;Cxcl10;Cxcl1;Cxcl5	0.00
GO:0019882	antigen processing and presentation	Rab10;Rab32;Relb	0.01
GO:0007249	I-kappaB kinase/NF-kappaB signaling	Bcl10;Nfkbia;Relb	0.02
GO:0002224	toll-like receptor signaling pathway	Tlr2;Tlr4	0.03
GO:0043065	positive regulation of apoptotic process	Bcl10;Creb1;Fas;Gadd45a;Mmp9;Phlda3; Sfrp1;Sox4;Tnfaip8;Trim35	0.03
GO:0009615	response to virus	Cxcl10;Dclk1;Oas3;Tgtp1;Gm12185	0.04
GO:0002376	immune system process	Aim2;Bcl10;C3;C4b;Oas3;Syk;Tgtp1; Gm12185;Tlr2;Tlr4;Zc3h12a	0.04

Table 5 Significantly enriched GO terms associated with immune response.

Table 6 Significantly enriched KEGG pathways associated with immune response.

pathway_id	pathway_name	Genes	p
ko04657	IL-17 signaling pathway	Ccl2;Ccl7;Cxcl10; Cxcl1;Cxcl5;Fos;Mmp9;Nfkbia;Tnfaip3	0.00
ko04668	TNF signaling pathway	Ccl2;Creb1;Cxcl10; Cxcl1;Fas;Fos;Mmp9;Nfkbia;Tnfaip3	0.00
ko04064	NF-kappa B signaling pathway	Bcl10;Nfkbia; Relb;Syk;Tlr4;Tnfaip3	0.00
ko04620	Toll-like receptor signaling pathway	Cxcl10;Fos;Nfkbia; Tlr2;Tlr4	0.02
ko04621	NOD-like receptor signaling pathway	Aim2;Ccl2;Cxcl1; Nfk- bia;Oas3;Tlr4;Tnfaip3	0.02
ko04062	Chemokine signaling pathway	Ccl2;Ccl7;Cxcl10;Cxcl1;Cxcl5;Elmo1;Nfkbia	0.03
ko04060	Cytokine-cytokine receptor interaction	Ccl2;Ccl7;Cxcl10;Cxcl1;Cxcl5;Fas;Ifngr2;Vegfc	0.04

miRNAs except for *mmu-miR-224-5p-R+1*, *mmu-miR-29b-3p* and *mmu-miR-93-3p-R+1* (Fig. 5B).

DISCUSSION

The effect of *E6* oncogene expression on miRNA and mRNA expression profiles in NIH/3T3 cells was unknown. Therefore, in this study, we focused on the BPV *E6* oncogene. The RNA sequencing analysis identified 350 DEGs in BPV *E6*-overexpressing NIH/3T3 cells compared with negative control cells. To investigate the major biological processes in which the DEGs were involved, we conducted GO analysis of the DEGs. Some significantly enriched immune-associated biological processes and corresponding immune associated genes are presented in Table 5. The expression of both *Cxcl5* and *Ccl7* increased more



Figure 4 miRNA-gene regulatory networks. (A) A miRNA-gene regulatory network based on upregulated miRNAs and downregulated genes. (B) A miRNA-gene regulatory network based on downregulated miRNAs and upregulated genes. Red and green represent up- and down-regulation, respectively. Rectangle and Round represent miRNAs and genes, respectively.

Full-size DOI: 10.7717/peerj.7442/fig-4







Figure 5 Validation of differentially expressed genes and miRNAs by qRT-PCR. (A) Validation of differentially expressed genes using qRT-PCR. Mouse GAPDH was as an internal control. (B) Validation of differentially expressed miRNAs using qRT-PCR. U6 snoRNA was as an internal control. Data from qRT-PCR assays are the means of three independent replicates, with error bars representing SD. Full-size DOI: 10.7717/peerj.7442/fig-5 than 10-fold in the BPV *E6* over-expressing NIH/3T3 cells compared with control cells. These results are consistent with those of a previous study in which gene expression profiles were used to identify candidate genes involved in the pathogenesis of equine skin tumors induced by BPV-1 infection (*Yuan et al., 2008*). Yuan et al. found that several genes enriched in inflammation and immunity, apoptosis and RNA transcription/metabolism were dysregulated; in particular, the expression of *Cxcl5* and *Ccl7* was significantly increased in BPV-1-transformed EqPalF cells. The Toll-like receptor (TLR) gene family plays a crucial role in recognizing pathogen-associated molecular patterns (PAMPs), which are conserved pathogen structures and ideal targets for recognize herpes simplex virus type 1 virions and mediate the release of inflammatory cytokines (*Kurt-Jones et al., 2004*), while Epstein-Barr virus induces Monocyte Chemotactic Protein 1 (MCP-1, also named CCL2) secretion by human monocytes through TLR2 (*Eric et al., 2007*). In our study, *Tlr2* and *Ccl2* were significantly upregulated in response to BPV-13 *E6* expression in NIH/3TR3 cells.

Accumulating evidence indicates that miRNAs play important roles in response to viral infection by directly targeting the viral genome or cellular genes (Fu et al., 2017; Ouyang et al., 2018; Slonchak et al., 2015). Terron-Canedo et al. (2017) used miRNA microarray analysis to investigate differentially expressed miRNAs in bovine papillomavirus type 1-transformed equine fibroblasts (EqPalF) compared with control cells. They found 206 differentially expressed mature miRNAs (p < 0.05, 144 downregulated, 62 upregulated) in EqPalFs transformed by the BPV-1 genome. The expression of six DE miRNAs (let-7b, miR-17/23b/132/143/181a) was confirmed by qPCR. This showed that miRNAs are involved in equine sarcoids and cell transformation. Previous studies reported that E6 oncoprotein from high-risk human papillomavirus type 16 (HPV16) or 18 (HPV18) inhibited the expression of tumor-suppressive miR-34a by degradation of p53, resulting in cell proliferation. HPV16 E6 also downregulated the expression of miR-23b, increased the expression of Urokinase-type plasminogen activator (uPA) and thus induced the migration of human cervical carcinoma SiHa and CaSki cells (Wang et al., 2009; Au Yeung et al., 2011). To explore miRNA changes in NIH/3T3 cells in response to BPV-13 E6 expression, we performed small RNA sequencing. Based on the filtering criteria, fold change ≥ 1.4 or fold change ≤ 0.71 , $p \leq 0.05$ and mean TPM ≥ 50 between NH-E6 samples and NH-GFP controls, we identified 23 upregulated and 15 downregulated miRNAs. The dysregulated miRNAs might participate in the biological process in response to BPV infection or in response to BPV E6. To investigate the potential functions of the differentially expressed miRNAs, a miRNA-gene regulatory network was constructed. Interestingly, we found that mmu-miR-582-5p was predicted to bind to Tlr2 and Cxcl5, which play crucial roles in the immune response to virus or other pathogens. Also, mmu-miR-129-2-3p potentially binds to Thbs1 and Sfrp1 and Sfrp1 suppresses hepatoma cell growth through the Wnt signaling pathway (Yu-Lueng et al., 2010). Also, downregulation of Srfp1 activates the Wnt pathway and contributes to cervical cancer progression (*Ming-Tzeung et al.*, 2009). These findings indicate that mmu-miR-129-2-3p might participate in the transformation process by targeting Sfrp1, although the underlying mechanism remains unclear. The miRNA-gene network will be useful for delineating the complex cellular response to BPV *E6* expression and may provide new insights into the functions of BPV *E6*.

Although we identified several differentially expressed genes associated with the immune response and constructed a potential miRNA-gene regulatory network following BPV *E6* expression, the interactions between the miRNAs and their target genes as well as their potential functions in response to BPV *E6* remain to be further studied.

CONCLUSIONS

In the present study, RNA sequencing and small RNA sequencing were used to explore changes in mRNAs and miRNAs in E6 over-expressing NIH/3T3 cells compared with control cells. A total of 350 genes (181 upregulated and 169 downregulated) and 54 miRNAs (26 upregulated and 28 downregulated) were differentially expressed following E6 expression. The major significantly enriched GO terms in "biological process" were inflammatory response, innate immune response, immune response, immune system process, positive regulation of apoptotic process, and cell adhesion. A potential miRNAgene regulatory network was constructed. Upregulation of 12 genes: Ccl2, Ccl7, Cxcl1, Cxcl5, Tlr2, Nfkbia, Fas, Il1rl1, Ltbp1, Rab32 and Zc3h12a, Dclk1 and downregulation of four genes, Agtr2, Ptx3, Sfrp1 and Thbs1, were confirmed by qPCR. Ccl2, Ccl7, Cxcl1 and Cxcl5 were upregulated more than ten-fold in NH-E6 cells compared with NH-GFP controls. Upregulation of three miRNAs, mmu-miR-129-2-3p, mmu-miR-149-5p-R-2 and mmu-miR-222-3p, and downregulation of five miRNAs, mmu-miR-582-3p-R+1, mmu-miR-582-5p, mmu-miR-708-3p, mmu-miR-708-5p and mmu-miR-1197-3p, were confirmed by qPCR. Our study investigated the differential expression of mRNAs and miRNAs in NIH/3T3 cells in response to BPV E6 expression and provides new insights into the functions of the BPV E6 oncogene.

ACKNOWLEDGEMENTS

We thank Jeremy Allen, PhD, from Liwen Bianji, Edanz Group China for editing the English text of a draft of this manuscript.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was financially supported by the Hainan Natural Science Foundation Innovation Research Team Project (2017CXTD003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors: Hainan Natural Science Foundation Innovation Research Team Project: 2017CXTD003.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Feng Pang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Mengmeng Zhang performed the experiments, prepared figures and/or tables.
- Guohua Li performed the experiments.
- Zhenxing Zhang, Haifeng Huang, Xiaohong Yang, Yiying Zheng, Qi An and Luyin Zhang contributed reagents/materials/analysis tools.
- Baobao Li and Chengqiang Wang prepared figures and/or tables.
- Li Du approved the final draft.
- Fengyang Wang conceived and designed the experiments, approved the final draft.

Data Availability

The following information was supplied regarding data availability:

Data is available at Gene Expression Omnibus database: GSE129592 and GSE129593.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.7442#supplemental-information.

REFERENCES

- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Gerald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the unification of biology. *Nature Genetics* 25(1):25–29 DOI 10.1038/75556.
- Au Yeung CL, Tsang TY, Yau PL, Kwok TT. 2011. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. *Oncogene* **30(21)**:2401–2410 DOI 10.1038/onc.2010.613.
- Bernard HU, Burk RD, Chen Z, Doorslaer KV, Hausen HZ, Villiers EMDJV. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology* **401**:70–79 DOI 10.1016/j.virol.2010.02.002.
- Bowie AG, Haga IR. 2005. The role of Toll-like receptors in the host response to viruses. *Molecular Immunology* 42:859–867 DOI 10.1016/j.molimm.2004.11.007.
- Chen J, Shi X, Zhang X, Wang A, Wang L, Yang Y, Deng R, Zhang G-PJJov. 2017. MicroRNA 373 facilitates the replication of porcine reproductive and respiratory syndrome virus by its negative regulation of type I interferon induction. *Journal of Virology* **91**:e01311–01316.
- **Cheng AM, Byrom MW, Jeffrey S, Ford LP. 2005.** Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. *Nucleic Acids Research* **33**:1290–1297 DOI 10.1093/nar/gki200.

- Dvoretzky I, Shober R, Chattopadhyay SK, Lowy DR. 1980. A quantitative in vitro focus assay for bovine papilloma virus. *Virology* 103(2):369–375 DOI 10.1016/0042-6822(80)90195-6.
- Eric G, Stéphanie F, Martin O, Jean GJJoV. 2007. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. *Journal of Virology* **81**:8016–8024 DOI 10.1128/JVI.00403-07.
- Fu M, Wang B, Chen X, He Z, Wang Y, Li X, Cao H, Zheng SJJJoV. 2017. gga-miR-130b suppresses infectious bursal disease virus replication via targeting the viral genome and cellular SOCS5. *Journal of Virology* **92**: JVI.01646-01617.
- Gene Ontology Consortium. 2018. The Gene Ontology resource: 20 years and still going strong. *Nucleic Acids Research* 47(D1):D330–D338 DOI 10.1093/nar/gky1055.
- Jackson ME, Pennie WD, Mccaffery RE, Smith KT, Grindlay GJ, Campo MSJMC. 1991. The B subgroup bovine papillomaviruses lack an identifiable E6 open reading frame. *Molecular Carcinogenesis* 4:382–387 DOI 10.1002/mc.2940040510.
- Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. 2017. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Research* **45(D1)**:D353–D361 DOI 10.1093/nar/gkw1092.
- Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 2011. KEGG for integration and interpretation of large-scale molecular data sets. *Nucleic Acids Research* 40(D1):D109–D114 DOI 10.1093/nar/gkr988.
- Krol J, Loedige IWJNRG. 2010. The widespread regulation of microRNA biogenesis, function and decay. *Nature Reviews Genetics* 11(9):597–610 DOI 10.1038/nrg2843.
- Kumar A, Kumar A, Ingle H, Kumar S, Mishra R, Verma MK, Biswas D, Kumar NS, Mishra A, Raut AAJJoV. 2018. MicroRNA hsa-miR-324-5p suppresses H5N1 virus replication by targeting the viral PB1 and host CUEDC2.JVI.01057-01018-. *Journal of Virology* 92(19):e01057-18.
- Kurt-Jones EA, Melvin C, Shenghua Z, Jennifer W, George R, Roderick B, Arnold MM, Knipe DM, Finberg RW. 2004. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. *Proceedings of the National Academy of Sciences of the United States of America* 101:1315–1320 DOI 10.1073/pnas.0308057100.
- Lubna N, Saveria CM. 2010. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. *Veterinary Dermatology* 19:243–254.
- Ming-Tzeung C, Hung-Cheng L, Huey-Kang S, Ming-De Y, Yu-Lueng S, Cheng-Chang C, Mu-Hsien Y, Hang-Seng L, Da-Wei C, Ya-Wen L. 2009. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. *Gynecologic Oncology* 112:646–653 DOI 10.1016/j.ygyno.2008.10.026.
- **Munday JS. 2014.** Bovine and human papillomaviruses a comparative review. *Veterinary Pathology* **51**:1063–1075 DOI 10.1177/0300985814537837.
- Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno KJO. 2006. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. *Oncogene* 25:2537–2545 DOI 10.1038/sj.onc.1209283.

- **OBrien V, Campo MS. 1998.** BPV-4 E8 transforms NIH3T3 cells, up-regulates cyclin? A and cyclin A-associated kinase activity and de-regulates expression of the cdk inhibitor p27Kip1. *Oncogene* **17(3)**:293–301 DOI 10.1038/sj.onc.1201937.
- Ouyang W, Qian J, Pan QX, Wang JY, Xia XX, Wang XL, Zhu YM, Wang YS. 2018. ggamiR-142-5p attenuates IRF7 signaling and promotes replication of IBDV by directly targeting the chMDA5's 3' untranslated region. *Veterinary Microbiology* 221:74–80 DOI 10.1016/j.vetmic.2018.05.018.
- Pang F, Zhang M, Yang X, Li G, Zhu S, Nie X, Cao R, Yang X, Zhang Z, Huang H. 2019. Genome-wide analysis of circular RNAs in goat skin fibroblast cells in response to Orf virus infection. *PeerJ* 7:e6267 DOI 10.7717/peerj.6267.
- **Roperto S, Munday JS, Corrado F, Goria M, Roperto F. 2016.** Detection of bovine papillomavirus type 14 DNA sequences in urinary bladder tumors in cattle. *Veterinary Microbiology* **190**:1–4 DOI 10.1016/j.vetmic.2016.04.007.
- Sébastien P, Mihaela Z, Grässer FA, Minchen C, Russo JJ, Jingyue J, Bino J, Enright AJ, Debora M, Chris S. 2004. Identification of virus-encoded microRNAs. *Science* 304(5671):734–736 DOI 10.1126/science.1096781.
- Shafti-Keramat S, Schellenbacher C, Handisurya A, Christensen N, Reininger B, Brandt S, Kirnbauer R. 2009. Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. *Virology* **393**:1–6 DOI 10.1016/j.virol.2009.07.036.
- Slonchak A, Shannon RP, Pali G, Khromykh AA. 2015. Human miRNA miR-532-5p exhibits antiviral activity against West Nile virus via suppression of host genes SESTD1 and TAB3 required for virus replication. *Journal of Virology* **90**: JVI.02608-02615.
- Suprynowicz FA, Disbrow GL, Simic V, Schlegel R. 2005. Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16? *Virology* 332(1):102–113 DOI 10.1016/j.virol.2004.11.011.
- Tang WF, Huang RT, Chien KY, Huang JY, Lau KS, Jheng JR, Chiu CH, Wu TY, Chen CY, Horng JT. 2016. Host miR-197 plays a negative regulatory role in the enterovirus 71 infectious cycle by targeting the RAN protein. *Journal of Virology* 90:1424–1438 DOI 10.1128/JVI.02143-15.
- **Terron-Canedo N, Weir W, Nicolson L, Britton C, Nasir L. 2017.** Differential expression of microRNAs in bovine papillomavirus type 1 transformed equine cells. *Veterinary* & *Comparative Oncology* **15(3)**:764–774.
- **Tong X, Howley PM. 1997.** The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. *Proceedings of the National Academy of Sciences of the United States of America* **94**:4412–4417 DOI 10.1073/pnas.94.9.4412.
- Tong X, Salgia R, Li JL, Griffin JD, Howley PM. 1997. The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. *The Journal of Biological Chemistry* 272:33373–33376 DOI 10.1074/jbc.272.52.33373.
- Wade R, Brimer N, Pol SV. 2008. Transformation by bovine papillomavirus type 1 E6 requires paxillin. *Journal of Virology* 82(12):5962–5966 DOI 10.1128/JVI.02747-07.

- Wang X, Wang HK, Mccoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM. 2009. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. *RNA* 15(4):637–647 DOI 10.1261/rna.1442309.
- Yu-Lueng S, Chung-Bao H, Hung-Cheng L, Ming-De Y, Tsai-Yuan H, You-Chen C, Ya-Wen LJIJoC. 2010. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. *International Journal of Cancer* 121:1028–1035.
- **Yuan Z, Nicolson L, Marchetti B, Gault E, Campo M, Nasir LJJov. 2008.** Transcriptional changes induced by bovine papillomavirus type 1 in equine fibroblasts. *Journal of Virology* **82**:6481–6491 DOI 10.1128/JVI.00429-08.